Nepafenac boosts cataract surgery results in diabetic retinopathy patients

08/28/2013 | Healio

Only 3.2% of diabetic retinopathy patients who took nepafenac ophthalmic suspension 0.1% developed macular edema at 90 days following cataract surgery, compared with 16.7% of those who received vehicle treatment, a study revealed. Researchers also noted better visual acuity and fewer lost letters in the nepafenac arm than those in the vehicle group. The results were presented at the American Society of Retina Specialists meeting.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC